10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010)
By: tawkaw OpenCourseWare
Read the rest here:
10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010) - Video
Posted: December 3, 2014 at 7:46 pm
10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010)
By: tawkaw OpenCourseWare
Read the rest here:
10 Regenerative Medicine and Applications of Stem Cell Research June 1, 2010) - Video
Posted: December 3, 2014 at 7:59 am
Every year I do predictions for the stem cell field for the coming year. You can see my full post on my predictions for this year here.
Stay tuned soon for my predictions for 2014.
Howd I do for 2013 with my predications?
Each prediction for this year that I made last year is bolded and my assessment now of how I did for each is in green or red.I did reasonably well for 2013. Sometimes predictions get mixed in with what hopes or thinks would be the best thing to happen not necessarily the most likely.
10. At least two new lawsuits are filed against stem cell businesses, most likely by patients.I think the number is more likely to be 3-4, but lets see what develops.
RIGHT. There was a lawsuit filed in Japan against a stem cell clinic and some stem cell companies sued each other. Admittedly, I thought wed see more patient-based lawsuits.
9.No human iPS cell clinical trials start in 2013.More likely to begin in 2014, which will be exciting. I think this is actually good news compared to moving too fast.
WRONG. Dr. Takahashis iPS cell-based study for macular degeneration began to enroll patients on Aug. 1.
8. Transdifferentiation makes a major advance.
The rest is here:
Celltex Mexico | Knoepfler Lab Stem Cell Blog
Posted: December 3, 2014 at 7:57 am
By eHow Contributor
There are some good reasons to be cautiously optimistic about looking at stem cell companies as investment opportunities. Pres. Obama has already removed Bush administration restrictions on federal funding of controversial embryonic stem cell research, for example. Washington lawmakers have introduced legislation to futher loosen restrictions. Some stem cell companies are likely to benefit from that in the form of National Institutes of Health and other federal research grants, though perhaps not as much as universities and other biomedical research institutions. But remember that most stem cell companies are working with stem cells derived from other sources: fat tissue, umbilical cord blood, placentas, amniotic fluid, induced pluripotent stem (iPS) cells derived from tissues like skin, etc. One company actively involved in embryonic stem cell research is Geron Corp., which in January 2009 announced that the U.S. Food and Drug Administration had finally lifted a seven-month hold on its application for clinical trials of a human embryonic stem cell-based treatment that can be applied within seven to 14 days of acute spinal cord injuries. But some analysts were less than impressed with the announcement, noting that it will be a long time (summer 2009) before the trial starts. And there's no guarantee the Phase I safety trial will succeed and move on to Phase II. Some analysts have been very critical of the company, noting that its only real success has been in raising money, not bringing drugs to market. (This can be said of a lot of stem cell companies.)
But Geron is only one of 27 companies involved in stem cell research that are conducting or recruiting for clinical trials in a wide range of diseases and disorders. (Another 60+ companies aren't even close to testing a therapy on humans.) Fourteen of the 27 are publicly traded, here and abroad. With that in mind, here are some tips if you are interested in investing in stem cell research companies sooner or later.
Computer
Internet connection
Start watching these companies closely, paying attention to the progress of their clinical trials, their financial health, strategic research partnerships, etc. Go to their Web sites and add yourself to the press release or financial report distribution list. (There's a link in the Resources section below to a Web page that provides contact and clinical trial information on both the public and private companies with products being tested in the clinic.)
Pay close attention to companies that are in partnerships with bigger, more established pharmaceutical firms with deep pockets. Pfizer, for example, is actively embracing smaller companies with promising technologies or products (like stem cells for research). Pfizer already has arrangements with companies like Stem Cell Sciences (UK) and EyeCyte (U.S.), and more may be in the works. PerkinElmer bought and absorbed ViaCell in 2007. Watch for developments involving GlaxoSmithKline in the future. Biomedical research supply company Invitrogen (now Life Technologies) last year took a minority position in a stem cell company called Q Therapeutics.
Remember that most stem cell research companies are at the preclinical (animal research) stage (or are just emerging from that stage) and have no products on the market. Their revenue, if any, is derived from licensing of patented technology, from venture capital and public financing, from "milestone" payments related to research partnerships, and from research grants. So the old rule of thumb about sales and earnings doubling every decade is inappropriate in this context.
No matter what companies you're interested in, pay attention to another old rule of thumb: stay away from companies that are too heavily in debt, even if the debt is held by inside shareholders.
Take a close look at the management. It's always good when top executives are major stock owners. They have a real incentive to get the company growing and keep it growing.
Read this article:
How to Invest in Stem Cell Companies | eHow
Posted: December 3, 2014 at 7:54 am
The issue of stem cell research, particularly embryonic stem cell research, became a high-profile political issue in the U.S. during the first year of President George W. Bush's term in office (2001). On August 9, 2001, Bush enacted a ban on federal spending for the purpose of deriving new embryonic stem cells from fertilized embryos. He argued that performing research on embryos is destroying human life, and should therefore be avoided. Both the 109th and 110th Congresses passed bills overturning the ban, but both were vetoed by Bush. During the 109th Congress, both houses also passed and Bush signed a bill banning the creation of human fetuses with the sole purpose of destroying them and harvesting their body parts. The Senate also passed a bill encouraging research into the creation of stem cell lines without destroying human embryos.
While both Democrats and Republicans have advocated for expanded federal funding for stem cell research, the debate over embryonic stem cells tends to be more polarized. Democrats are generally supportive of expanding embryonic research, while Republicans tend to favor expanding only other types of stem cell research that do not involve the harming of human embryos. [1]
Opponents of federal funding for embryonic stem cell research, including the Heritage Foundation, have argued that [more here].
Legislation governing stem cells in the 110th Congress (2007-2008) generally fell into two categories: bills seeking to expand the funding of embryonic stem cell research and bills seeking to expand stem cell research without using human embryonic stem cells.
The principle vehicle for expanding the federal funding of embryonic stem cell research in 2007 was the Stem Cell Research Enhancement Act of 2007 (H.R.3).
On January 11, 2007, the Democratic-controlled House passed the Stem Cell Research Enhancement Act of 2007 (H.R.3), sponsored by Rep. Diana DeGette (D-Colo.), lifting the restriction on new federal funding for embryonic stem-cell research implemented by President Bush in 2001. Under this bill, the Secretary of Health and Human Services would be directed to conduct and support research that utilizes human embryonic stem cells. [2]
Under the bill, the cells eligible for use would be required to come from excess human embryos, smaller than the head of a pin, donated from in-vitro fertilization clinics. The cells would have had to have been created for the purpose of fertility treatment. Once a woman was successfully fertilized, the extra cells could be donated for research. In particular, the bill required that prior to the consideration of donating the embryo and through consultation with individuals seeking fertility treatment, it must have been determined that the embryos would never be implanted in a woman and would otherwise be discarded.[3]
To avoid cell farming and other efforts to profit from providing stem cells, the bill would require that the individuals seeking fertility treatment donate the embryos with written informed consent and without receiving any financial or other inducements to make the donation.[4]
The final vote was 253-174, thirty-seven votes short of a veto-proof majority. As expected, President Bush promised to veto the bill if it reached his desk. The White House issued a statement saying, "The administration strongly opposes House passage of H.R. 3, which would use federal taxpayer dollars to support and encourage the destruction of human life for research...If H.R. 3 were presented to the president, he would veto the bill."[5]
Read more from the original source:
U.S. federal stem cell legislation - SourceWatch
Posted: December 3, 2014 at 7:54 am
Featured in the News Across the Nation: Dr. Dennis Lox, an Expert in Sports & Regenerative Medicine, Discusses Stem Cell Therapy:
Since 1990, Dennis M. Lox, M.D. has been helping patients increase their quality of life by reducing their pain. He emphasizes non-surgical treatments and appropriate use of medications, if needed.
Many patients are turning to stem cell therapy as a means of nonsurgical joint pain relief when their mobility and quality of life are severely affected by conditions like osteoarthritis, torn tendons, and injured ligaments. Dennis M. Lox, M.D. specializes in this progressive, innovative treatment that may be able to help you return to an active, fulfilling life.
Each week, Dr. Dennis Lox receives inquiries from around the world regarding stem cell therapy.
Stem cell therapy for joint injuries and osteoarthritis is suited for many individuals, fromprofessional athletes to active seniors. Adult mesenchymal stem cells, not embryonic stem cells, are used in this procedure, which is performed right in the comfort of Dr. Loxs state-of-the-art clinic. The cells are simply extracted from the patients own body (typically from bone marrow or adipose/ fat tissue), processed in our office, and injected directly into the site of injury. Conditions that can be addressed with stem cell treatment include osteoarthritis, degenerative disc disease, knee joint issues (such as meniscus tears), shoulder damage (such as rotator cuff injuries), hip problems (such as labral tears), and tendonitis, among others. For many patients, a stem cell procedure in the knee, hip, shoulder, or another area of the body relieves pain, increases mobility, and may be able to delay or eliminate the need for more aggressive treatments like joint replacement surgery.
PRP Therapy, Stem Cell Treatments & Other Joint Replacement Alternatives for Patients in Tampa, Clearwater, New Port Richey & throughout the U.S.A. and the world.
If you are searching for effective, nonsurgical joint replacement alternatives, regenerative therapies like stem cell treatments and PRP therapy may be the ideal solution. At Florida Spine and Sports Medicine, we focus on helping patients return to mobile, independent lives without the need for the risks and downtime associated with highly invasive surgery.
View post:
Dr Lox - Tampa Stem Cell Therapy | PRP | Knee | Joint ...
Posted: December 3, 2014 at 1:47 am
New York, Dec 3 (IANS): Using DNA from stored blood samples, an Indian-origin scientist Dhruv Sareen have developed a novel method to re-create brain and intestinal stem cells from patients who died decades ago and long-ago volunteered their blood samples.
The research could lead to new therapies for people who suffer from aggressive motor-neuron and gut-related conditions such as inflammatory bowel disease.
"The potential implications of this research are vast," said the study's lead author Sareen from Cedars-Sinai Medical Center in Los Angeles, California.
By using a deceased patient's stored blood samples, the researchers found that they can develop stem cells known as iPSCs in a petri dish - essentially reanimating diseased cells from patients long after they have died.
This approach allows researchers to connect the dots between a deceased patient's symptoms, genetic information contained in DNA and the behaviour of stem cells in the lab.
This, in turn, enables investigators to study the biological mechanisms behind diseases and potentially design new therapies.
The technique also allows physicians to replace invasive biopsy procedures typically required of living patients to create iPSC cells.
"These novel developments allow us to create new lines of stem cells from literally millions of patient samples stored in large repositories," said Clive Svendsen from Cedars-Sinai Medical Center.
The study was published in the journal STEM CELLS Translational Medicine.
Stay updated wherever you go with Daijiworld.com and Daijiworld 24X7 tv channel mobile apps. CLICK HERE to download it for your device. (available on Android and IOS)
Read more here:
Stem cells from the dead to help health research
Posted: December 3, 2014 at 1:47 am
PUBLIC RELEASE DATE:
1-Dec-2014
Contact: Cara Martinez cara.martinez@cshs.org 310-423-7798 Cedars-Sinai Medical Center @cedarssinai
LOS ANGELES (Dec. 1, 2014) - Research scientists have developed a novel method to re-create brain and intestinal stem cells from patients who died decades ago, using DNA from stored blood samples to study the potential causes of debilitating illnesses such as inflammatory bowel disease.
The lab research, published in the journal STEM CELLS Translational Medicine, could yield new therapies for people who suffer from aggressive motor-neuron and gut-related conditions that proved fatal to the deceased patients who long-ago volunteered their blood samples.
"The potential implications of this research are vast," said Dhruv Sareen, PhD, the study's lead author, and assistant professor and director of the David and Janet Polak Foundation Stem Cell Core Laboratory in the Board of Governors Regenerative Medicine Institute.
By using a deceased patient's stored blood samples, Sareen and his colleagues found that they can develop stem cells known as iPSCs in a petri dish - essentially reanimating diseased cells from patients long after they have died.
This approach allows researchers to connect the dots between a deceased patient's symptoms, genetic information contained in DNA and the behavior of stem cells in the lab. This, in turn, enables investigators to study the biological mechanisms behind diseases and potentially design new therapies.
The technique also allows physicians to replace invasive biopsy procedures typically required of living patients to create iPSC cells.
"These novel developments allow us to create new lines of stem cells from literally millions of patient samples stored in large repositories," said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute. "Some of these deceased patients were diagnosed with rare and important diseases."
Read this article:
Researchers recreate stem cells from deceased patients to study present-day illnesses
Posted: December 3, 2014 at 1:47 am
Nov. 26, 2014, 3:13 a.m.
It is hoped that a trial due to start next year, and involving about 20 Australian children with cerebral palsy, will show the benefits of using stem cells from their own umbilical cord blood to treat the condition.
About 20 Australian children with cerebral palsy will be infused with their own umbilical cord blood in a trial due to start next year, as physicians warn families against travelling overseas for experimental stem cell treatments.
The long-awaited Australian trial will provide some of the world's first evidence about the safety and effectiveness of using stem cells from umbilical cord blood to repair brain injury that leads to cerebral palsy.
Researchers are waiting on ethics approval for the trial which will provide treatment to families who have chosen to store their child's cord blood at private banks.
In some cases, children with cerebral palsy will be able to receive a sibling's cord blood if this is available.
Cerebral Palsy Alliance head of research Iona Novak said the study, led by the Murdoch Childrens Research Institute, will recruit children from around Australia who have access to privately banked cord blood.
Children aged one to 10 will receive infusions at private blood banks in Melbourne, Sydney and Brisbane, and will be assessed before and after the treatment to check for improvements.
Researchers will be unable to access cord blood from a public bank, which collects blood to treat blood disorders such as leukaemia and cannot be used for untested new therapies.
Associate Professor Novak said the trial was an important first step towards establishing whether stem cells could help repair the brain injury that leads to cerebral palsy, a series of disabilities associated with movement and posture.
View post:
Stem cell trial to begin for children suffering from cerebral palsy
Posted: December 3, 2014 at 1:44 am
TESTIMONI LAMININE - Ginjal Diabetes dan Komplikasi
Kunjungi website kami http://lamininestemcell.com Contacts: LIA MASTURA Phone: 081214804542 | WA: 088218497617 PIN BB: 7E97FF36 MIRA MASTURA Phone: 089657194720.
By: Laminine Nutrisi Stem Cell Terbaik
Read the rest here:
TESTIMONI LAMININE - Ginjal Diabetes dan Komplikasi - Video
Posted: December 3, 2014 at 1:41 am
NEWS
1200+ scientists, patient advocates from 40 countries in town for summit
Posted YESTERDAY, 6:04 PM Updated YESTERDAY, 6:33 PM
SAN ANTONIO - More than a thousand scientists, industry leaders and patient advocates from 40 countries are headed to San Antonio for the World Stem Cell Summit.
Organizers are calling it the center of the universe when it comes to stem cells and regenerative medicine.
On Tuesday the summit kicked off with Public Education Day, where some of the smartest scientists in the field broke the topic down into bite-sized pieces.
"To be able to replenish our cells that die within a tissue on a daily basis, in order for us to be able to heal wounds, we have to have stem cells," said Elaine Fuchs, an investigator for the Howard Hughes Medical Institute.
She started her research in the field in the 1970s with work on skin stem cells, and said she was fascinated with creating skin in a petri dish that could then be used for burn therapy.
Fuchs spoke at Public Education Day about the most basic biology of stem cells and said that knowledge is leading to a new world in medicine.
"The biology of stem cells is gong to be and is being extremely valuable in terms of developing new therapies and coming up with new drugs to treat various different devastating diseases," Fuchs said.
Follow this link:
World Stem Cell Summit kicks off in SA with Public Education Day